🩺The 2025 Medicare bid cycle was challenging for all stakeholders, let’s dive in with Milliman’s actuarial experts to discuss how this impacts life sciences organizations. 💡 Join Milliman’s Medicare Part D experts as they discuss lessons from this year’s bid cycle and provide critical insights and answer pressing questions including: •New formulary strategies •Disruptions to plan membership •Changes in plan benefits •Impact of the new Part D design on patients' out-of-pocket costs Speakers: Matthew Hayes, Ryan Swenson, Peter Heinen, FSA, MAAA Moderator: Maggie Alston Don't miss out on this opportunity to stay ahead of the curve! Register now! #Milliman #MillimanLifeSciencesLive #Medicare
2025 Medicare Bid Cycle: Life Sciences Insights
www.linkedin.com
Do you expect payers to restrict pharmacy networks?
What other levers and strategies outside of UM do you see payers implementing to manage costs?
What percentage of members do you think will participate in the M3P program?
Do you expect manufacturers will delay drug launches to game IRA drug negotiations?
What is the IRA impact to PBM in your view ?
How did the predictions of the National Average Bid Amount line up with what Milliman expected? And what if anything can be gleaned from the regional low-income benchmarks, which in some states show substantial reductions?